LANGHORNE, Pa., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will be participating in The Microcap Conference, which will take place January 30th through February 1st at the Ceasars Atlantic City Hotel & Casino in Atlantic City, New Jersey.
Presentation Details:
Wednesday, January 31st, 10:25 – 10:45 AM and
Thursday, February 1st at 3:35 – 3:55 PM
Interested parties can register to attend here.
Management will be available for 1x1 meetings throughout the event. To schedule a 1x1 meeting, please contact your Microcap Conference representative or send an email to This email address is being protected from spambots. You need JavaScript enabled to view it..
About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.68 |
Daily Change: | -0.16 -5.63 |
Daily Volume: | 27,297 |
Market Cap: | US$16.940M |
June 11, 2024 May 13, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB